BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. (“MyMD”) and Akers Biosciences, Inc. (“Akers”) (NASDAQ: AKER) collectively introduced a definitive merger settlement final week. The corporations plan to maintain a video convention for buyers on Wednesday, November 18, 2020 at 4:15 p.m. ET to present extra context on the built-in firm, the scientific pipeline and drug improvement plan, and the business potential of the focused indications.
To take part within the briefing session, please click on on the hyperlink beneath to register.
About Akers Biosciences Inc.
Akers Biosciences is pursuing fast improvement and manufacturing of a COVID-19 vaccine candidate in collaboration with Premas Biotech PVT Ltd.
About MyMD Pharmaceuticals, Inc:
MyMD is a scientific stage pharmaceutical firm dedicated to extending wholesome lifespan by specializing in creating two therapeutic platforms. MYMD-1 is a drug platform based mostly on a scientific stage small molecule that regulates the immunometabolic system to management TNF-α and different pro-inflammatory cytokines. MYMD-1 is being developed to deal with autoimmune ailments, together with these presently handled with TNF-α blocking medicine, and getting old and longevity. SUPERA-1R is a drug platform based mostly on a novel (patent pending) artificial by-product of cannabidiol (CBD) that targets quite a few key receptors together with CB2 and opioid receptors and inhibits monoamine oxidase. SUPERA-1R is being developed to handle the quickly rising CBD market, that features FDA accepted medicine and CBD merchandise not presently regulated as a drug. For extra info, go to www.mymd.com.
No Offer or Solicitation
This communication shall not represent a proposal to promote or the solicitation of a proposal to promote or the solicitation of a proposal to purchase any securities, nor shall there be any sale of securities in any jurisdiction during which such supply, solicitation or sale could be illegal prior to registration or qualification underneath the securities legal guidelines of any such jurisdiction. No public supply of securities shall be made besides via a prospectus assembly the necessities of Section 10 of the Securities Act of 1933, as amended.
Important Additional Information Will be Filed with the SEC
In connection with the proposed transaction between Akers and MyMD, Akers intends to file related supplies with the SEC, together with a registration assertion that can comprise a proxy assertion and prospectus. AKERS URGES INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AKERS, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and shareholders can be in a position to get hold of free copies of the proxy assertion, prospectus and different paperwork filed by Akers with the SEC (once they change into out there) via the web site maintained by the SEC at www.sec.gov. In addition, buyers and shareholders can be in a position to get hold of free copies of the proxy assertion, prospectus and different paperwork filed by Akers with the SEC by contacting Investor Relations by mail at Akers Biosciences, Inc., Attn: Investor Relations, 201 Grove Road, West Deptford, NJ 08086. Investors and stockholders are urged to learn the proxy assertion, prospectus and the opposite related supplies once they change into out there earlier than making any voting or funding resolution with respect to the proposed transaction.
Participants within the Solicitation
Akers and MyMD, and every of their respective administrators and govt officers and sure of their different members of administration and staff, could also be deemed to be contributors within the solicitation of proxies in connection with the proposed transaction. Information about Akers’ administrators and govt officers is included in Akers’ Annual Report on Form 10-Okay for the 12 months ended December 31, 2019, filed with the SEC on March 25, 2020, as amended on October 21, 2020, and the proxy assertion for Akers’ 2020 annual assembly of stockholders, filed with the SEC on July 29, 2020. Additional info relating to these individuals and their pursuits within the transaction can be included within the proxy assertion relating to the transaction when it’s filed with the SEC. These paperwork might be obtained freed from cost from the sources indicated above.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained on this communication relating to issues that aren’t historic info are forward-looking statements inside the that means of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, often known as the PSLRA. These embrace statements relating to administration’s intentions, plans, beliefs, expectations or forecasts for the longer term, and, subsequently, you might be cautioned not to place undue reliance on them. No forward-looking assertion might be assured, and precise outcomes could differ materially from these projected. Akers and MyMD undertake no obligation to publicly replace any forward-looking assertion, whether or not because of new info, future occasions or in any other case, besides to the extent required by regulation. We use phrases corresponding to “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and comparable expressions to determine these forward-looking statements which might be supposed to be lined by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based mostly on our expectations and contain dangers and uncertainties; consequently, precise outcomes could differ materially from these expressed or implied within the statements due to a lot of components, together with, however not restricted to, dangers relating to the completion of the merger, together with the necessity for stockholder approval and the satisfaction of closing situations; the money balances of the mixed firm following the closing of the merger; the flexibility of Akers to stay listed on the Nasdaq Capital Market in connection with the merger; and anticipated merger-related money outlays, together with the timing and quantity of these outlays. Risks and uncertainties associated to MyMD which will trigger precise outcomes to differ materially from these expressed or implied in any forward-looking assertion embrace, however aren’t restricted to: the timing of, and MyMD’s means to, get hold of and preserve regulatory approvals for scientific trials of MyMD’s pharmaceutical candidates, the timing and outcomes of MyMD’s deliberate scientific trials for its pharmaceutical candidates, the quantity of funds MyMD requires for its pharmaceutical candidates; elevated ranges of competitors; adjustments in political, financial or regulatory situations typically and within the markets during which MyMD operates; MyMD’s means to retain and entice senior administration and different key staff; MyMD’s means to rapidly and successfully reply to new technological developments; MyMD’s means to shield its commerce secrets and techniques or different proprietary rights, function with out infringing upon the proprietary rights of others and stop others from infringing on MyMD’s proprietary rights; and the impression of the continuing COVID-19 pandemic on MyMD’s outcomes of operations, marketing strategy and the worldwide economic system.
New components emerge from time to time and it isn’t potential for us to predict all such components, nor can we assess the impression of every such issue on the enterprise or the extent to which any issue, or mixture of things, could trigger precise outcomes to differ materially from these contained in any forward-looking statements. These dangers, in addition to different dangers related with the mixture, can be extra absolutely mentioned within the proxy assertion/prospectus that can be included within the registration assertion that can be filed with the SEC in connection with the proposed transaction. Additional dangers and uncertainties are recognized and mentioned within the “Risk Factors” part of Akers’ Annual Report on Form 10-Okay, Quarterly Reports on Form 10-Q and different paperwork filed from time to time with the SEC. Forward-looking statements included on this launch are based mostly on info out there to Akers and MyMD as of the date of this launch. Neither Akers nor MyMD undertakes any obligation to replace such forward- trying statements to mirror occasions or circumstances after the date of this launch.